Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase Ⅰ Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of GT20029 Gel and Solution for Single and Multi Dose External Administration in Healthy Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase Ⅰ Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of GT20029 Gel and Solution for Single and Multi Dose External Administration in Healthy Subjects

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GT 20029 (Primary)
  • Indications Acne vulgaris; Alopecia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Suzhou Kintor Pharmaceuticals

Most Recent Events

  • 28 Aug 2023 According to a Kintor Pharmaceutical Limited media release, the study will be presented at EADV 2023
  • 10 Feb 2023 According to a Kintor Pharmaceutical Limited media release, the study demonsrtated the good safety and tolerability in MAD of GT20029.
  • 09 Aug 2022 According to a Kintor Pharmaceutical Limited media release, leading principal investigators (leading PIs) of the trial are Professor Zhang Jing and Associate Professor Wu Xiaojie from Huashan Hospital affiliated to Fudan University.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top